News
AZ gets FDA nod for Enhertu in first HER2-low cancer
The FDA has approved AstraZeneca and Daiichi Sankyo's Enhertu as the first targeted therapy for HER2-low breast cancer, a new category of the disease that was once lumped under the HER2-neg
